1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014

Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Breast Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Metastatic Breast Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Metastatic Breast Cancer 25
Subjects Recruited Over a Period of Time 43
Clinical Trials by Sponsor Type 44
Prominent Sponsors 45
Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials 46
Prominent Drugs 48
Latest Clinical Trials News on Metastatic Breast Cancer 49
Feb 27, 2014: Eisai Announces Initiation of a Phase 3 Trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in First and Second Lines of Metastatic Breast Cancer 49
Jan 14, 2014: Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 49
Oct 21, 2013: Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer 50
Sep 03, 2013: Oncothyreon Announces Initiation of Phase 1 Trial of ONT-380 in Combination with Trastuzumab in Patients with Brain Metastases from HER2+ Breast Cancer 51
Jul 30, 2013: Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer 52
Clinical Trial Profiles 53
Clinical Trial Overview of Top Companies 53
F. Hoffmann-La Roche Ltd. 53
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 53
Novartis AG 67
Clinical Trial Overview of Novartis AG 67
GlaxoSmithKline plc 75
Clinical Trial Overview of GlaxoSmithKline plc 75
Eli Lilly and Company 81
Clinical Trial Overview of Eli Lilly and Company 81
AstraZeneca PLC 85
Clinical Trial Overview of AstraZeneca PLC 85
Pfizer Inc. 89
Clinical Trial Overview of Pfizer Inc. 89
Sanofi 93
Clinical Trial Overview of Sanofi 93
Bristol-Myers Squibb Company 97
Clinical Trial Overview of Bristol-Myers Squibb Company 97
Johnson and Johnson 101
Clinical Trial Overview of Johnson and Johnson 101
Celgene Corporation 103
Clinical Trial Overview of Celgene Corporation 103
Clinical Trial Overview of Top Institutes / Government 105
National Cancer Institute 105
Clinical Trial Overview of National Cancer Institute 105
The University of Texas M. D. Anderson Cancer Center 120
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 120
Memorial Sloan Kettering Cancer Center 124
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 124
Sarah Cannon Research Institute 126
Clinical Trial Overview of Sarah Cannon Research Institute 126
North Central Cancer Treatment Group 128
Clinical Trial Overview of North Central Cancer Treatment Group 128
European Organization for Research and Treatment of Cancer 130
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 130
FUDAN University 132
Clinical Trial Overview of FUDAN University 132
UCLA's Jonsson Comprehensive Cancer Center 134
Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center 134
Vanderbilt-Ingram Cancer Center 135
Clinical Trial Overview of Vanderbilt-Ingram Cancer Center 135
Five Key Clinical Profiles 136
Appendix 206
Abbreviations 206
Definitions 206
Research Methodology 207
Secondary Research 207
About GlobalData 208
Contact Us 208
Disclaimer 208
Source 209

List of Tables
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Metastatic Breast Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Metastatic Breast Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Metastatic Breast Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 43
Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 44
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 45
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 47
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 48
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 53
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 67
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 75
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 81
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 85
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 89
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 93
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 97
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 101
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 103
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 105
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 120
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 124
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarah Cannon Research Institute, 2014* 126
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 128
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 130
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 132
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by UCLA's Jonsson Comprehensive Cancer Center, 2014* 134
Metastatic Breast Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt-Ingram Cancer Center, 2014* 135

List of Figures
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 43
Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 44
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 45
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 46
Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 48
GlobalData Methodology 207

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.